The nation of Zimbabwe has rejected a significant US health deal worth $367m (272 million pounds) spanning five years due to the United States' request for confidential data.
The decision was revealed after a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa believed the agreement was "unbalanced".
A government spokesman later stated that the US was seeking biological samples for research and commercial purposes while refused to guarantee the benefits from any future medical innovations.
"We must now begin the difficult and regrettable task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for continued negotiations to secure a agreement suitable to all parties so the country's vital HIV programme can continue.
Wider Background
This development follows a comparable situation in neighbouring Kenya, where a court blocked a similar health funding agreement following legal challenges were raised about the safety of citizens' medical information.
Since resuming office last year, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had overseen aid for the US government, but Trump stated its spending was "inefficient" and his government was pursuing government-to-government deals to boost transparency and responsibility.
As per reports, Sixteen African countries have so far signed similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no equivalent promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Effectively, our nation would supply the basic resources for medical research with no assurance that the end products would be available to our citizens should a new pandemic arise."
Sovereignty and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining frameworks already established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with potential global health emergencies.
"This framework is designed to guarantee that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how subsequent collaboration could be designed in a manner that respects the independence and dignity of each country."
Health Experts Response
Medical experts expressed it recognised the official position, but suggested that talks must proceed since much of the country's HIV programmes depended on foreign aid.
"Where technical issues exist, including those relating to data governance or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," the group added.
The halted deal underscores the continuing tensions between accepting much-needed foreign assistance and safeguarding a country's data in an ever more interconnected world.